DUBLIN, Ireland, Nov. 04, 2017 (GLOBE NEWSWIRE) — Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced results from a new open-label study evaluating the effects of PROCYSBI® (cysteamine bitartrate) delayed-release capsules in treatment-naïve children younger than 6 years of age living with nephropathic cystinosis.